Skip to search formSkip to main contentSkip to account menu

olaratumab

Known as: Anti-PDGFR alpha Monoclonal Antibody IMC-3G3, Anti-Platelet-Derived Growth Factor Receptor alpha Monoclonal Antibody IMC-3G3 
A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

7 relations
50 ML olaratumab 10 MG/ML Injection [Lartruvo]Antibody-Dependent Cellular CytotoxicityNCIt Antineoplastic Agent Terminologyantigen binding

Broader (2)

Antineoplastic AgentsMonoclonal Antibodies

Narrower (1)

IMC-3G3

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).
LBA3 Background: Dox is standard therapy in STS. In a Ph 2 trial, olaratumab (a human IgG1 antibody targeting PDGFRα) + dox… 
2019
2019
Olaratumab for STS Disappoints in Phase III.
Two years after receiving accelerated approval from the FDA as first-line therapy with doxorubicin for patients with advanced or… 
Review
2018
Review
2018
Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
Lartruvo® (olaratumab) is a fully human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that inhibits platelet-derived… 
Review
2018
Review
2018
EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives.
2018
2018
Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
Olaratumab, a monoclonal antibody targeting human platelet‐derived growth factor receptor α, plus doxorubicin significantly… 
Review
2017
Review
2017
Olaratumab for advanced soft tissue sarcoma
ABSTRACT Introduction: Olaratumab is a humanized IgG1 monoclonal antibody that blocks the platelet-derived growth factor receptor… 
2017
2017
Approvals in 2016: cost–benefit challenges of new anticancer agents
In 2016, four new anticancer drugs were approved by the FDA, and a further 12 existing agents were approved for 14 additional… 
Review
2017
Review
2017
Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma
Objective: To review and summarize data on olaratumab, which was approved by the US Food and Drug Administration (FDA) in October… 
2016
2016
Olaratumab Approved for Soft-Tissue Sarcoma.
The FDA has granted accelerated approval to the monoclonal antibody olaratumab, combined with doxorubicin, as first-line therapy… 
2014
2014
Phase I study of olaratumab in Japanese patients with advanced solid tumors
Olaratumab (IMC‐3G3) is a fully human IgG1 monoclonal antibody that selectively binds the external domain of human platelet… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)